Clinical Trial of CD40L-Augmented TIL for Advanced Melanoma
Phase 1/2
36
about 4.4 years
18+
1 site in FL
What this study is about
This trial is testing a single dose of CD40L-augmented TIL in patients with advanced melanoma. Patients will undergo lymphodepletion followed by the TIL product and standard of care interleukin-2.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cyclophosphamide
- 2.Take Fludarabine
- 3.Take Interleukin-2
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, immunotherapy (Cytokine; stimulates T-cells to proliferate)
infusion
Primary: Phase I: Treatment Emergent Adverse Events (TEAE), Phase II: Objective Response Rate
Secondary: Duration of response, Overall survival, Progression Free Survival (PFS)
Oncology